Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: An update
Identifieur interne : 005A66 ( Main/Exploration ); précédent : 005A65; suivant : 005A67Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: An update
Auteurs : Mark R. Denison [États-Unis]Source :
- The Pediatric infectious disease journal [ 0891-3668 ] ; 2004.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Animaux, Anticorps antiviraux, Enfant, Facteurs de l'âge, Flambées de maladies, Humains, Indice de gravité médicale, Modèles animaux de maladie humaine, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (physiopathologie), Syndrome respiratoire aigu sévère (transmission), Vaccins antiviraux (immunologie), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité), Zoonoses.
- MESH :
- immunologie : Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- pathogénicité : Virus du SRAS.
- physiopathologie : Syndrome respiratoire aigu sévère.
- Pascal (Inist)
- Adolescent, Adulte, Animaux, Anticorps antiviraux, Enfant, Facteurs de l'âge, Flambées de maladies, Humains, Indice de gravité médicale, Modèles animaux de maladie humaine, Syndrome respiratoire aigu sévère, Hépatite, Immunoprophylaxie, Pathogénie, Prévention, Vaccin, Coronavirus, Souche atténuée, Animal, Souris, Enfant, Réplication, Modèle animal, Protéine, Pédiatrie, Zoonoses.
- Wicri :
English descriptors
- KwdEn :
- Adolescent, Adult, Age Factors, Animal, Animal model, Animals, Antibodies, Viral, Attenuated strain, Child, Coronavirus, Disease Models, Animal, Disease Outbreaks, Hepatitis, Humans, Immunoprophylaxis, Mouse, Pathogenesis, Pediatrics, Prevention, Protein, Replication, SARS Virus (immunology), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (physiopathology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (transmission), Severe acute respiratory syndrome, Severity of Illness Index, Vaccine, Viral Vaccines (immunology), Zoonoses.
- MESH :
- chemical , immunology : Viral Vaccines.
- chemical : Antibodies, Viral.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- physiopathology : Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- transmission : Severe Acute Respiratory Syndrome.
- Adolescent, Adult, Age Factors, Animals, Child, Disease Models, Animal, Disease Outbreaks, Humans, Severity of Illness Index, Zoonoses.
Abstract
Background: A novel coronavirus has recently been identified as the cause of severe acute respiratory syndrome (SARS-CoV). The ability of this family of positive strand RNA viruses to move between species and cause severe disease in humans, with the potential for pandemic spread, has been confirmed. Methods: An understanding of the disease and its pathogenesis and the genetics of coronavirus infections, as well as strategies to treat or prevent coronavirus infections, are essential. The history of coronavirus vaccines and the occurrence of laboratory-associated SARS-CoV infections underscore the need for stably attenuated strains of SARS-CoV and other coronaviruses. Results: Rapid progress has been made in understanding the clinical disease of SARS in adults and children. In adults, systemic infection with clinical and biochemical abnormalities, as well as respiratory infection, may be the rule. SARS is much milder in children younger than 12 years old than it is in adolescents and adults. In children age 12 years and younger, symptoms are generally nonspecific and cold-like. Numerous approaches to the development of SARS-CoV vaccines have been undertaken, and there is evidence that antibodies to the spike protein may be protective from replication and pathology in animal models. Conclusions: The availability of reverse genetic systems has made it possible to engineer and recover coronavirus variants that contain multiple genetically stable mutations that grow well in culture but are attenuated for replication, virulence or both. Such variants will be platforms for the safe growth of SARS-CoV and candidates for live attenuated vaccines.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000757
- to stream PascalFrancis, to step Curation: 000233
- to stream PascalFrancis, to step Checkpoint: 000769
- to stream Main, to step Merge: 005F20
- to stream PubMed, to step Corpus: 002A18
- to stream PubMed, to step Curation: 002A18
- to stream PubMed, to step Checkpoint: 002A42
- to stream Ncbi, to step Merge: 000C44
- to stream Ncbi, to step Curation: 000C44
- to stream Ncbi, to step Checkpoint: 000C44
- to stream Main, to step Merge: 005449
- to stream Main, to step Curation: 005A66
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: An update</title><author><name sortKey="Denison, Mark R" sort="Denison, Mark R" uniqKey="Denison M" first="Mark R." last="Denison">Mark R. Denison</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Pediatrics and Microbiology and Immunology, Vanderbilt University Medical Center</s1><s2>Nashville, TN</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Tennessee</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0014471</idno><date when="2004">2004</date><idno type="stanalyst">PASCAL 05-0014471 INIST</idno><idno type="RBID">Pascal:05-0014471</idno><idno type="wicri:Area/PascalFrancis/Corpus">000757</idno><idno type="wicri:Area/PascalFrancis/Curation">000233</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000769</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000769</idno><idno type="wicri:doubleKey">0891-3668:2004:Denison M:severe:acute:respiratory</idno><idno type="wicri:Area/Main/Merge">005F20</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15577575</idno><idno type="wicri:Area/PubMed/Corpus">002A18</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A18</idno><idno type="wicri:Area/PubMed/Curation">002A18</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A18</idno><idno type="wicri:Area/PubMed/Checkpoint">002A42</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A42</idno><idno type="wicri:Area/Ncbi/Merge">000C44</idno><idno type="wicri:Area/Ncbi/Curation">000C44</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C44</idno><idno type="wicri:doubleKey">0891-3668:2004:Denison M:severe:acute:respiratory</idno><idno type="wicri:Area/Main/Merge">005449</idno><idno type="wicri:Area/Main/Curation">005A66</idno><idno type="wicri:Area/Main/Exploration">005A66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: An update</title><author><name sortKey="Denison, Mark R" sort="Denison, Mark R" uniqKey="Denison M" first="Mark R." last="Denison">Mark R. Denison</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Pediatrics and Microbiology and Immunology, Vanderbilt University Medical Center</s1><s2>Nashville, TN</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Tennessee</region></placeName></affiliation></author></analytic><series><title level="j" type="main">The Pediatric infectious disease journal</title><title level="j" type="abbreviated">Pediatr. infect. dis. j.</title><idno type="ISSN">0891-3668</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Pediatric infectious disease journal</title><title level="j" type="abbreviated">Pediatr. infect. dis. j.</title><idno type="ISSN">0891-3668</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Animal</term><term>Animal model</term><term>Animals</term><term>Antibodies, Viral</term><term>Attenuated strain</term><term>Child</term><term>Coronavirus</term><term>Disease Models, Animal</term><term>Disease Outbreaks</term><term>Hepatitis</term><term>Humans</term><term>Immunoprophylaxis</term><term>Mouse</term><term>Pathogenesis</term><term>Pediatrics</term><term>Prevention</term><term>Protein</term><term>Replication</term><term>SARS Virus (immunology)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (physiopathology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (transmission)</term><term>Severe acute respiratory syndrome</term><term>Severity of Illness Index</term><term>Vaccine</term><term>Viral Vaccines (immunology)</term><term>Zoonoses</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Anticorps antiviraux</term><term>Enfant</term><term>Facteurs de l'âge</term><term>Flambées de maladies</term><term>Humains</term><term>Indice de gravité médicale</term><term>Modèles animaux de maladie humaine</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (physiopathologie)</term><term>Syndrome respiratoire aigu sévère (transmission)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (pathogénicité)</term><term>Zoonoses</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Animals</term><term>Child</term><term>Disease Models, Animal</term><term>Disease Outbreaks</term><term>Humans</term><term>Severity of Illness Index</term><term>Zoonoses</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Anticorps antiviraux</term><term>Enfant</term><term>Facteurs de l'âge</term><term>Flambées de maladies</term><term>Humains</term><term>Indice de gravité médicale</term><term>Modèles animaux de maladie humaine</term><term>Syndrome respiratoire aigu sévère</term><term>Hépatite</term><term>Immunoprophylaxie</term><term>Pathogénie</term><term>Prévention</term><term>Vaccin</term><term>Coronavirus</term><term>Souche atténuée</term><term>Animal</term><term>Souris</term><term>Enfant</term><term>Réplication</term><term>Modèle animal</term><term>Protéine</term><term>Pédiatrie</term><term>Zoonoses</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term><term>Enfant</term><term>Pédiatrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: A novel coronavirus has recently been identified as the cause of severe acute respiratory syndrome (SARS-CoV). The ability of this family of positive strand RNA viruses to move between species and cause severe disease in humans, with the potential for pandemic spread, has been confirmed. Methods: An understanding of the disease and its pathogenesis and the genetics of coronavirus infections, as well as strategies to treat or prevent coronavirus infections, are essential. The history of coronavirus vaccines and the occurrence of laboratory-associated SARS-CoV infections underscore the need for stably attenuated strains of SARS-CoV and other coronaviruses. Results: Rapid progress has been made in understanding the clinical disease of SARS in adults and children. In adults, systemic infection with clinical and biochemical abnormalities, as well as respiratory infection, may be the rule. SARS is much milder in children younger than 12 years old than it is in adolescents and adults. In children age 12 years and younger, symptoms are generally nonspecific and cold-like. Numerous approaches to the development of SARS-CoV vaccines have been undertaken, and there is evidence that antibodies to the spike protein may be protective from replication and pathology in animal models. Conclusions: The availability of reverse genetic systems has made it possible to engineer and recover coronavirus variants that contain multiple genetically stable mutations that grow well in culture but are attenuated for replication, virulence or both. Such variants will be platforms for the safe growth of SARS-CoV and candidates for live attenuated vaccines.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Tennessee</li></region></list><tree><country name="États-Unis"><region name="Tennessee"><name sortKey="Denison, Mark R" sort="Denison, Mark R" uniqKey="Denison M" first="Mark R." last="Denison">Mark R. Denison</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005A66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005A66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:05-0014471
|texte= Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: An update
}}
| This area was generated with Dilib version V0.6.33. |  |